Form 4: T2 Biosystems Director David B. Elsbree Sells Shares
SEC Form 4 Filing
Director David B. Elsbree of T2 Biosystems sold 55 shares of common stock on September 13, 2024.
Summary
- On September 13, 2024, David B. Elsbree, a director of T2 Biosystems, Inc., sold 55 shares of common stock at a price of $2.42 per share.
- Following the transaction, Elsbree directly owns 23 shares of T2 Biosystems common stock.
- Elsbree also indirectly owns shares through a spouse.
Sentiment
Score: 5
Explanation: The sentiment is neutral. It's a small transaction, and there's no clear indication of positive or negative implications.
Negatives
- A director selling shares could be interpreted negatively by the market.
Risks
- Insider selling activity can sometimes signal a lack of confidence in the company's future prospects, although this sale is small.
Industry Context
Insider trading activity is closely monitored in the biotech industry, as it can provide insights into management's perspective on the company's prospects. However, small transactions like this are not always indicative of a larger trend.
Stakeholder Impact
- The sale of shares by a director could potentially cause concern among shareholders, although the small size of the transaction may mitigate this impact.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Date of transaction: Sale of 55 shares of common stock. |
| 09/17/2024 | Date of signature on the Form 4 filing. |
Keywords
T2 Biosystems, Insider Trading, Form 4, Elsbree, Director, Share Sale, TTOO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.